Effectiveness and safety of  hypofractionated radiation therapy in postmastectomy breast cancer

Tovanabutra C; Katanyoo K; Chomprasert K; Uber P; Sookauychai S

Authors

Tovanabutra C Chonburi Cancer Hospital, Thailand
Katanyoo K Department of Radiology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Thailand
Chomprasert K Radiation Oncology section, Chonburi Cancer Hospital, Department of Medical servives, Ministry of Public Health, Thailand
Uber P Radiation Oncology Section, Chonburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, Thailand
Sookauychai S Medical Oncology Section, Chonburi Cancer Hospital, Department of Medical Services, Ministry of Public Health, Thailand

Keywords:

Hypofractionated radiotherapy, Postmastectomy breast cancer

Abstract

Objectives Hypofractionated radiotherapy (HFRT) is an alternative treatment in postmastectomy breast cancer
women. This study was conducted to assess the effectiveness and safety of HFRT at the Chonburi Cancer Hospital by
evaluating the outcomes of treatment.

Methods Clinical and demographic characteristics of 486 breast cancer patients with mastectomy who had received
complete adjuvant radiotherapy treatment between January 2012 and December 2015 were retrospectively analyzed.
All patients had received HFRT 2.65-2.67 Gy daily for 15-18 fractions for a total dose of 39.75-47.86 Gy. The study
outcomes included 5-year local recurrence free survival (LRFS), disease free survival (DFS), and overall survival (OS)
including grade 2 or more acute and late toxicities in different age groups.

Results The median follow-up was 66.1 months (range 2.1-100.4 months). Five-year LRFS was 93.7%, five-year DFS
was 61.5% and 5-year OS was 66.4%. There was slightly higher grade 3 arm edema and cardiovascular toxicity in the
> 60 age group. There were no differences in the incidence rates of other toxicities including skin atrophy, subcutaneous
tissue fibrosis, brachial plexopathy and pulmonary fibrosis among the different age groups.

Conclusions The implementation of HFRT in postmastectomy breast cancer patients is both effective and safe. HFRT is
particularly beneficial during the COVID-19 pandemic as it consumes fewer hospital resources.

References

Overgaard M, Hansen PS, Overgaard J, Rose C, An-dersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast can-cer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949-55.

Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Co-operative Group DBCG 82c randomised trial. Lancet. 1999; 353(9165):1641-8.

Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in pa-tients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116-26.

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastec-tomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of indi-vidual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127-35.

Fowler JF. The linear-quadratic formula and pro-gress in fractionated radiotherapy. Br J Radiol. 1989; 62(740):679-94. 6. Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010; 362:513-20.

FAST Trialists group, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, Bloomfield D,et al. First results of the randomised UK FAST Trial of radiotherapy hy-pofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100:93-100.

Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofrac-tionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013; 14:1086-94.

Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, et al. Hypofractionated versus conventional fraction-ated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019; 20:352-60.

Chitapanarux I, Klunklin P, Pinitpatcharalert A, Sripan P, Tharavichitkul E, Nobnop W, et al. Conventional ver-sus hypofractionated postmastectomy radiotherapy: a report on long-term outcomes and late toxicity. Radiat Oncol. 2019;14:175.

Liu L, Yang Y, Guo Q, Ren B, Peng Q, Zou L, et al. Com-paring hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a me-ta-analysis and systematic review. Radiat Oncol. 2020; 15:17.

Tovanabutra C, Katanyoo K, Uber P, Chomprasert K, Sukauichai S. Comparison of treatment outcome be-tween hypofractionated radiotherapy and conventional radiotherapy in postmastectomy breast cancer. Asian Pac J Cancer Prev. 2020; 21:119-125.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471-4.

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Ra-diation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31:1341-6.

Bajrovic A, Rades D, Fehlauer F, Tribius S, Hoeller U, Rudat V, et al. Is there a life-long risk of brachial plex-opathy after radiotherapy of supraclavicular lymph nodes in breast cancer patients? Radiother Oncol. 2004; 71:297-301.

Harris SR, Hugi MR, Olivotto IA, Levine M; Steering Committee for Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ. 2001;164:191-9.

Bochenek-Cibor J, Georgiew F, Goyal S. A retrospective analysis on safety and effectiveness of hypofractioned post-mastectomy radiotherapy. Breast J. 2020; 26:176-81.

Khan M, Siddiqui SA, Gupta MK, Seam RK, Gupta M. Normal tissue complications following hypofractionat-ed chest wall radiotherapy in breast cancer patients and their correlation with patient, tumor, and treatment characteristics. Indian J Med Paediatr Oncol. 2017;38: 121-7.

Sardar P, Kundu A, Chatterjee S, Nohria A, Nairooz R, Bangalore S, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic re-view and meta-analysis. Clin Cardiol. 2017;40:73-81.

King V, Constine LS, Clark D, Schwartz RG, Muhs AG, Henzler M, et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease. Int J Ra-diat Oncol Biol Phys. 1996; 36:881-9.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gi-etema JA, Duane FK, et al. Cardiovascular disease in-cidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Br J Cancer. 2018; 119:408-18.

Yadav BS, Bansal A, Kuttikat PG, Das D, Gupta A, Da-hiya D. Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer. Radiat Oncol J. 2020;38:109-118.

Gałecki J, Hicer-Grzenkowicz J, Grudzień-Kowalska M, Michalska T, Załucki W. Radiation-induced bra-chial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer a review. Acta Oncol. 2006;45:280-4.